OMA Vendor Directory
Find great resources for your obesity medicine practice.
Search the Obesity Medicine Association’s Vendor Directory to find the right resources for your practice. Vendors listed offer a variety of products, services, technologies, and solutions for your obesity medicine practice.
Disclaimer: The Obesity Medicine Association (OMA) presents a forum for its members to be exposed to various products and services. It is the responsibility of each member to do due diligence, including reviewing literature, lectures, and background information. The individual is also responsible for becoming familiar with laws on prescribing limitations within his or her own state before practicing various therapies. OMA does not endorse, approve, or sponsor any products or services.
Browse by Category:
Regeneron
An Obesity Medicine Association Corporate Council Member
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous approved treatments and product candidates in development.
Zealand Pharma
An Obesity Medicine Association Corporate Council Member
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S.
Showing 1-2 of 2 results
Vendor Directory Listing
Submit your application for your organization to be listed in the Vendor Directory. Organizations are listed in the online directory and included in the monthly OMA newsletter.